GlassScriptPhysician profile
Nadia S Wang
NPI 1447289699
$3,433.01
in general payments reported to CMS, 2019-2025
27 companies · $874 in 2025
The $874 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $176 · 2021: $181 · 2022: $555 · 2023: $559 · 2024: $661 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $476.24 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $407.32 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $358.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $309.33 | 2019-2025 | Ilumya |
| Abbvie INC. | $294.33 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $216.32 | 2019-2023 | Adbry |
| Ucb, INC. | $180.63 | 2022-2025 | Bimzelx |
| Incyte Corporation | $174.50 | 2022-2025 | Opzelura |
| Pfizer INC. | $151.19 | 2019-2025 | |
| Amgen INC. | $140.07 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $127.31 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Lilly USA, LLC | $117.59 | 2019-2025 | Ebglyss, Taltz, Zepbound |
| Arcutis Biotherapeutics, INC. | $88.87 | 2024-2025 | Zoryve |
| Organon LLC | $50.93 | 2025 | |
| Mayne Pharma Commercial LLC | $47.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $41.37 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.80 | 2024-2025 | Cabtreo, Jublia |
| Biofrontera INC. | $38.50 | 2020-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Mission Pharmacal Company | $33.11 | 2022 | |
| Aclaris Therapeutics, INC. | $29.46 | 2019 | |
| Dermavant Sciences, INC. | $27.38 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $22.44 | 2023 | Ycanth |
| Sandoz INC. | $17.41 | 2024 | Hyrimoz |
| Galderma Laboratories, L.P. | $14.85 | 2023 | |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Prugen, INC. Pharmaceuticals | $12.14 | 2020 | |
| Strata Skin Sciences, INC. | $0.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.